Haloperidol Arena

Haloperidol Arena is an oral, prescription medication that contains the active ingredient haloperidol. Marketed in the European Union, it belongs to the butyrophenone class of antipsychotics and is listed under ATC code N05AD01. The product is supplied as tablets (strength may vary by market) and is intended for use under medical supervision for conditions such as schizophrenia, acute psychotic episodes, Tourette syndrome, and severe agitation.

Haloperidol Arena is prescribed for several psychiatric and neurological conditions where dopamine blockade is therapeutic.

- Schizophrenia (including maintenance therapy). - Acute psychotic episodes associated with mood disorders or substance use. - Tourette syndrome with prominent motor or vocal tics. - Severe agitation or aggression in hospitalized patients. - Short‑term control of psychosis in patients unable to tolerate other antipsychotics. - Management of psychotic symptoms in patients with comorbid neurological disorders such as Huntington’s disease. - Adjunctive therapy for refractory aggression in dementia when other options are insufficient.

Haloperidol Arena may produce a range of adverse effects that reflect its activity at dopamine, histamine, adrenergic, and muscarinic receptors.

Common: - Drowsiness or sedation, which may affect alertness and driving ability. - Dry mouth, often leading to increased thirst or difficulty swallowing. - Constipation, potentially requiring dietary fiber or laxatives. - Extrapyramidal symptoms such as mild tremor, rigidity, or restlessness (akathisia). - Weight gain or increased appetite, which can contribute to metabolic changes.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by high fever, muscle rigidity, autonomic instability, and altered mental status. - Tardive dyskinesia, a potentially irreversible movement disorder presenting as repetitive, involuntary facial or limb movements after long‑term therapy. - Severe orthostatic hypotension, causing sudden drops in blood pressure upon standing and possible fainting.

When prescribing Haloperidol Arena, clinicians consider several precautionary factors to minimize risk and ensure safe use.

- Assess for a history of cardiovascular disease, as haloperidol can affect heart rhythm. - Evaluate for prior extrapyramidal reactions or movement disorders. - Use caution in patients with hepatic or renal impairment because metabolism may be altered. - Monitor elderly patients closely, especially those with dementia, due to increased sensitivity to sedation and falls. - Consider pregnancy and breastfeeding status; data are limited, so benefits must outweigh potential risks. - Review concomitant medications that may prolong QT interval.

Haloperidol Arena can interact with other medicines that influence its metabolism or additive pharmacologic effects.

Avoid: - Other antipsychotics or dopamine antagonists, which may increase risk of extrapyramidal symptoms. - Medications that markedly prolong the QT interval, such as certain antiarrhythmics or fluoroquinolones. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.

Use with caution: - CYP2D6 substrates (e.g., metoprolol, codeine) because haloperidol may affect their metabolism. - CNS depressants including benzodiazepines, opioids, or alcohol, which can enhance sedation. - Antihypertensive agents, as orthostatic hypotension may be potentiated.